Day: November 8, 2018

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018.

From Startup Xynomic Pharma Link to Full Article: http://xynomicpharma.com/en/1811-2/ Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018. Mr. Xu will present at 12:55 pm on Tuesday, November 13, 2018 at Ballroom I, 5th

Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update

From Startup Kezar Life Sciences Link to Full Article: http://investors.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-reports-third-quarter-2018-financial-results SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter

Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results

From Startup Magenta Therapeutics Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-reports-recent-operational-progress-and-0 –Nine clinical and preclinical abstracts accepted for presentation at American Society of Hematology (ASH) annual meeting – – Continued to strengthen robust intellectual property position – – Ended quarter with $159.7M in cash and cash equivalents – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 8,

Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update

From Startup Arbutus Bio Link to Full Article: http://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-2018-third-quarter-financial-results-and – AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial – ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus Third

Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors

From Startup Neon Therapeutics Link to Full Article: Seasoned executive brings more than 20 years of biopharmaceutical industry experience CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the appointment of Robert Bazemore to its Board of Directors. Mr. Bazemore is

Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review

From Startup Merrimack Pharmaceuticals Link to Full Article: http://investors.merrimackpharma.com/news-releases/news-release-details/merrimack-reports-third-quarter-2018-financial-results-and CAMBRIDGE, Mass., Nov. 7, 2018 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a research and clinical development oncology company focused on biomarker-defined cancers, today announced its third quarter 2018 financial results for the period ended September 30, 2018 and provided a strategic

Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates

From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-announces-second-fiscal-quarter-2018-financial-results First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s disease Expanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy (OPMD) and collaboration agreement for five additional neurological gene therapy

BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2375846 Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics

Myovant Strengthens Management Team and Adds New Directors to the Board

From Startup Myovant Link to Full Article: http://investors.myovant.com/news-releases/2018/11-07-2018-133112398 BASEL, Switzerland, Nov. 7, 2018 /PRNewswire/ — Myovant Sciences, Ltd. (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases, today announced that Kim Sablich, formerly Vice President of Primary Care Marketing in the